Floatz logo

Plerixafor

Adult Oligodendroglial Tumors

Lawrence RechtSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Oligodendroglial Tumors cohort.

Asset / SponsorPhaseRating
Temsirolimus
National Cancer Institute (NCI)
Phase 1/2CCC
Perifosine
National Cancer Institute (NCI)
Phase 1/2CCC
Alisertib
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 1CC
Isotretinoin
Wake Forest University Health Sciences
Phase 1CC
FDOPA
Erik Mittra
Early Phase 1CC

View all 10 →

Same molecule, other indications

Plerixafor is also rated in:

Fanconi anemiaDormant
BB
Indicative ·
70 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →